2025
Longitudinal Evaluation of Immune Checkpoint Inhibitor‐Induced Fatigue Syndrome by Rest, Stress, and Speckle‐Tracking Strain Echocardiography
Tsai K, Chang A, Abouzeid C, Aras M, Fang Q, Bibby D, Haghighat L, Hilton J, Daud A, Schiller N. Longitudinal Evaluation of Immune Checkpoint Inhibitor‐Induced Fatigue Syndrome by Rest, Stress, and Speckle‐Tracking Strain Echocardiography. Echocardiography 2025, 42: e70158. PMID: 40198654, DOI: 10.1111/echo.70158.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsGlobal longitudinal strainSystolic functionInitiation of immune checkpoint inhibitorsImmune checkpoint inhibitor initiationLV global longitudinal strainSpeckle-tracking strain echocardiographyLA global strainSubclinical cardiac toxicitySystolic function measurementsCardiac systolic functionAnti-tumor therapyMonitor cardiac functionBiventricular sizeCheckpoint inhibitorsCardiac toxicityEchocardiographic parametersPeak heart rateStrain echocardiographyLVOT VTICardiac functionPeak exerciseCancer patientsVelocity timeLongitudinal strain
2024
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Amini A, Zaha V, Hamad E, Woodard P, Rimner A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Higgins K, Iyengar P, Juloori A, Movsas B, Ning M, Park H, Rodrigues G, Wolf A, Simone C. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. Journal Of Thoracic Oncology 2024, 19: 1654-1667. PMID: 39313150, PMCID: PMC11665043, DOI: 10.1016/j.jtho.2024.09.1433.Peer-Reviewed Original ResearchConceptsCardiac toxicityCardiac comorbiditiesThoracic radiotherapyToxicity preventionAmerican Radium Society Appropriate Use CriteriaAbsence of cardiovascular risk factorsLow riskHigh riskMultidisciplinary consensus guidelinesTreatment-related risksAppropriate use criteriaCardiovascular risk factorsVariants of patientsThoracic malignanciesModified Delphi methodologyCardiac substructuresConsensus guidelinesRadiotherapyRisk factorsCardiac imagingComorbiditiesDose exposurePatientsSystematic reviewThoracic
2023
Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)
Lee S, Fan W, Wang A, Vaidya R, Redman M, Gettinger S, Bazhenova L, Herbst R, Hershman D, Unger J. Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). JCO Clinical Cancer Informatics 2023, 7: e2200165. PMID: 37084329, PMCID: PMC10281446, DOI: 10.1200/cci.22.00165.Peer-Reviewed Original ResearchConceptsSystem organ classAdverse event dataRandomized phase III trialPhase III trialsCell lung cancerOncology clinical trialsOverall toxicity profileIII trialsNeurologic toxicityTreatment armsCardiac toxicityLung cancerClinical trialsGrade 3High prevalenceOrgan classToxicity profileNivolumabTreatment groupsStage IVEndocrine toxicityType of AEToxicity typesAE termsIpilimumab
2021
The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity
Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg J, Friedman D, Schwartz C, Bergeron-Gravel S, Dama H, Roberts K, Constine L, Hodgson D. The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity. Blood 2021, 138: 881. DOI: 10.1182/blood-2021-147678.Peer-Reviewed Original ResearchInvolved site radiotherapyCardiac radiation doseInvolved-field radiotherapyChildhood Cancer Survivor StudyPositron emission tomographyMediastinal radiotherapyChildren's Oncology GroupDoxorubicin doseCumulative incidenceCardiac toxicityCardiac diseaseRT useCardiac riskCardiac disease riskBulk diseaseOncology GroupLymphoma trialsTrial protocolRadiation doseLong-term cardiac riskDisease riskCumulative doxorubicin doseImpact of nivolumabLate cardiac toxicityMean heart dosePost-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer 2021, 161: 171-179. PMID: 34607209, DOI: 10.1016/j.lungcan.2021.09.010.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyNon-small cell lung cancerCell lung cancerRadiation therapyPropensity-score matchingLA-NSCLCCardiac toxicityLung cancerAdvanced non-small cell lung cancerClinical risk factorsProportion of patientsMultivariable logistic regressionPrior treatment historyPredictors of receiptUse of IMRTConformal radiation therapyLong-term toxicityChi-squared testRadiation therapy techniquesRadiotherapy treatment techniquesUpfront surgeryElderly patientsTreatment toxicityMean ageMedicare databaseA Polyphenol-Rich Extract of Olive Mill Wastewater Enhances Cancer Chemotherapy Effects, While Mitigating Cardiac Toxicity
Albini A, Festa M, Ring N, Baci D, Rehman M, Finzi G, Sessa F, Zacchigna S, Bruno A, Noonan D. A Polyphenol-Rich Extract of Olive Mill Wastewater Enhances Cancer Chemotherapy Effects, While Mitigating Cardiac Toxicity. Frontiers In Pharmacology 2021, 12: 694762. PMID: 34434106, PMCID: PMC8381749, DOI: 10.3389/fphar.2021.694762.Peer-Reviewed Original ResearchHearts of miceSide effectsRat cardiomyocytesPotential cardioprotective activityEffect of chemotherapyProstate cancer xenograftsAdverse side effectsColon cancer cell growthCancer cell growthPolyphenol-rich extractAnti-oxidant activityAnti-cancer activityCardiovascular preventionCardioprotective effectsTumor weightCardiac toxicityCancer patientsCardiovascular toxicityCancer xenograftsCardioprotective roleProtective effectCancer chemotherapy effectsMouse pupsCardioprotective activityChemotherapy effect
2019
The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia
Strickland S, Podoltsev N, Mohan S, Zeidan A, Childress M, Ayers G, Byrne M, Gore S, Stuart R, Savona M. The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia. Blood 2019, 134: 180. DOI: 10.1182/blood-2019-131520.Peer-Reviewed Original ResearchIntermediate-dose cytarabineCR/CRiAdverse eventsOverall survivalInfusional cytarabineOral mucositisCardiac toxicityResponse assessmentCelgene CorporationAML ptsOral cryotherapyBoehringer IngelheimMedian ageCR rateDay 1Large randomized phase 3 trialsTwo-stage phase II studyClass anticancer quinolone derivativeCR/CRi rateRandomized phase 3 trialHematopoietic stem cell transplantAdvisory CommitteeDaiichi SankyoAcute cardiac toxicityIncomplete count recoveryThe Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics
Soufer A, Baldassarre LA. The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics. Current Treatment Options In Cardiovascular Medicine 2019, 21: 28. PMID: 31104180, DOI: 10.1007/s11936-019-0732-5.Peer-Reviewed Original ResearchCardiac magnetic resonanceCardiac toxicityCardiac magnetic resonance imagingNon-invasive workupImmune checkpoint inhibitorsSubclinical LV dysfunctionMyocardial tissue characteristicsCancer therapyPurpose of ReviewTheMagnetic resonance imagingCheckpoint inhibitorsLA fibrosisLV dysfunctionMicrocirculatory dysfunctionNon-invasive methodMagnetic resonanceCardiac structureResonance imagingMyocardial strainTissue characteristicsDysfunctionCancer therapeuticsTherapyToxicityFurther researchNuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods
Soufer A, Liu C, Henry ML, Baldassarre LA. Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. Journal Of Nuclear Cardiology 2019, 27: 1210-1224. PMID: 30868378, DOI: 10.1007/s12350-019-01671-6.Peer-Reviewed Original ResearchConceptsCardiac toxicityPre-clinical cardiotoxicityCardiac magnetic resonanceNuclear cardiologyCardiovascular outcomesNon-invasive imagingCardiovascular toxicityChemotherapeutic agentsCancer treatmentEarly detectionCardiac imagingCancer therapyCancer therapeuticsCardiologyToxicityMagnetic resonanceTreatmentImagingEchocardiographyPatientsCardiotoxicityTherapyCancerSeverityCareImmune Checkpoint Inhibitor–Associated Pericarditis
Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL. Immune Checkpoint Inhibitor–Associated Pericarditis. Journal Of Thoracic Oncology 2019, 14: 1102-1108. PMID: 30851443, PMCID: PMC6617516, DOI: 10.1016/j.jtho.2019.02.026.Peer-Reviewed Original ResearchConceptsAdverse eventsCTLA-4 inhibitorsImmune checkpoint inhibitorsDeath-1/Pericardial window procedureCheckpoint inhibitorsThird patientClinical presentationCardiac toxicityHistopathologic findingsSide effectsPericarditisPatientsDeath ligandsPotential mechanismsWindow procedureInhibitorsImmunotherapyNSCLCCardiotoxicityAutopsiesTherapy
2017
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart M, Suter T, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Research And Treatment 2017, 168: 631-638. PMID: 29280043, PMCID: PMC5843537, DOI: 10.1007/s10549-017-4628-3.Peer-Reviewed Original ResearchConceptsAnti-HER2 therapyNT-proBNPBiomarker elevationCardiac toxicityEarly predictorHER2-positive early-stage breast cancerEarly-stage breast cancerAnthracycline-naïve patientsEarly cardiac toxicityLevels of TnTNT-proBNP elevationBrain natriuretic peptideBreast cancer patientsNeoALTTO trialWeekly paclitaxelCardiac dysfunctionTreatment armsCardiac damageNatriuretic peptideCancer patientsCardiac biomarkersBreast cancerPatientsTroponin TAmino-terminal fragmentTrastuzumab emtansine: determining its role in management of HER2+ breast cancer
Doroshow DB, LoRusso PM. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Future Oncology 2017, 14: 589-602. PMID: 29214842, DOI: 10.2217/fon-2017-0477.Peer-Reviewed Original ResearchConceptsBreast cancerAnti-HER2 monoclonal antibody trastuzumabManagement of HER2Single-agent trastuzumabTumor-directed cytotoxicityAcceptable toxicity profileFirst-line treatmentPhase III trialsMonoclonal antibody trastuzumabAdjuvant managementIII trialsOverall survivalAdvanced HER2Cardiac toxicityTrastuzumab emtansineAgent trastuzumabToxicity profileAntibody trastuzumabSystemic toxicityHER2CancerTrastuzumabStable linkerOngoing studiesToxicityRadiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings
Hong JC, Rahimy E, Gross CP, Shafman T, Hu X, Yu JB, Ross R, Finkelstein SE, Dosoretz A, Park HS, Soulos PR, Evans SB. Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings. Practical Radiation Oncology 2017, 8: e79-e86. PMID: 28888675, DOI: 10.1016/j.prro.2017.07.005.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyMedian MHDCardiac riskRadiation therapyBreast cancerCardiac toxicityRisk of RTCommunity settingsLeft-sided breast cancerThree-dimensional conformal radiation therapyDeep inspiration breath holdCardiovascular risk factorsIschemic heart diseaseInspiration breath holdBreast cancer treatmentMultivariable linear regressionConformal radiation therapyCommunity practiceCardiac doseCardiac eventsBreast conservationMultivariable analysisMean heartContemporary community practiceExcess risk
2016
Radiation-induced heart disease in lung cancer radiotherapy
Ming X, Feng Y, Yang C, Wang W, Wang P, Deng J. Radiation-induced heart disease in lung cancer radiotherapy. Medicine 2016, 95: e5051. PMID: 27741117, PMCID: PMC5072944, DOI: 10.1097/md.0000000000005051.Peer-Reviewed Original ResearchConceptsRadiation-induced heart diseaseLung cancer radiotherapyLung cancer patientsPotential risk factorsCancer radiotherapyCancer patientsCardiac toxicityHeart diseaseRisk factorsRadiation treatmentLung cancer survivorsLate side effectsHistory of heartTypes of cancerCardiac complicationsCrude incidencePulmonary diseaseBetter prognosisLobar locationBenign diseaseCancer survivorsLung cancerTreatment modalitiesPatient prognosisBreast cancer
2015
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C
Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, Freilich B, Zamparo J, Brown K, Dimitrova D, Kumar M, Manion D, Heath-Chiozzi M, Wolf R, Hughes E, Muir AJ, Hernandez AF. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015, 62: 409-416. PMID: 25251156, DOI: 10.1002/hep.27488.Peer-Reviewed Original ResearchConceptsNucleotide polymerase inhibitorLVEF dysfunctionPolymerase inhibitorsB-type natriuretic peptide levelsChronic hepatitis C virus (HCV) infectionHepatitis C virus infectionActing antiviral (DAA) agentsSevere myocyte damageC virus infectionNatriuretic peptide levelsPhase II studyVentricular ejection fractionT-wave inversionOff-target toxicityHCV treatmentHepatitis CII studySystolic functionTransthoracic echocardiogramEjection fractionNew DAAsCardiac dysfunctionElectrocardiogram changesPathological findingsCardiac toxicity
2014
Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy
Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy. Clinical Lymphoma Myeloma & Leukemia 2014, 15: 292-297. PMID: 25499624, PMCID: PMC4409502, DOI: 10.1016/j.clml.2014.11.001.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaHigh-risk acute promyelocytic leukemiaConsolidation chemotherapyConsolidation therapyPromyelocytic leukemiaEffective consolidation therapyEvent-free survivalLeukemia-free survivalTrans retinoic acidArsenic trioxide combinationsChemotherapy regimenAnthracycline exposureOverall survivalSecondary malignanciesCardiac toxicityFavorable outcomeRetrospective analysisArsenic trioxideTherapyRetinoic acidChemotherapyPatientsSurvivalLeukemiaMonthsCardiac Toxicity in Intensity Modulated Radiation Therapy, Dynamic Conformal Arc Therapy, and Volumetric Modulated Arc Therapy of Lung Cancers
Ming X, Feng Y, Zhang Y, Zhou L, Deng J. Cardiac Toxicity in Intensity Modulated Radiation Therapy, Dynamic Conformal Arc Therapy, and Volumetric Modulated Arc Therapy of Lung Cancers. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s666-s667. DOI: 10.1016/j.ijrobp.2014.05.1963.Peer-Reviewed Original Research
2010
A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma.
Lansigan F, Seropian S, Cooper D, Potter V, Sowers N, Foss F. A Phase 1 Trial of Vorinostat and Pegylated Liposomal Doxorubicin In Relapsed or Refractory Lymphoma. Blood 2010, 116: 2816. DOI: 10.1182/blood.v116.21.2816.2816.Peer-Reviewed Original ResearchDose level 3Stem cell transplantStable diseaseHL patientsHodgkin's lymphomaPartial responseRefractory lymphomaCell transplantCardiac toxicityDisease progressionLiposomal doxorubicinLymphoplasmacytic lymphomaGrade 3Prior treatmentAST/ALT elevationAutologous stem cell transplantMedian age 69 yearsAllogeneic stem cell transplantPeripheral T-cell lymphomaTherapy warrants further investigationDisease controlLarge B-cell lymphomaDose level 1Dose level 2Doses of vorinostatCardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress In Cardiovascular Diseases 2010, 53: 94-104. PMID: 20728696, DOI: 10.1016/j.pcad.2010.05.006.Peer-Reviewed Original ResearchConceptsCardiac adverse effectsCardiac toxicityCardiovascular toxicityNew drug developmentLeft ventricular ejection fraction declineVentricular ejection fraction declineAdverse effectsClassic chemotherapy agentsEjection fraction declinePotential cardiovascular toxicityRare serious complicationsNovel biologic agentsSignificant cardiac dysfunctionAcute coronary syndromeCongestive heart failureLong-term complicationsTypes of malignanciesSystemic cancer therapyLife-threatening eventsCancer therapyTyrosine kinase inhibitorsDrug developmentCardiovascular safetyCoronary syndromeBiologic agents
2009
Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer
Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C. Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer 2009, 9: 101-107. PMID: 19433391, DOI: 10.3816/cbc.2009.n.019.Peer-Reviewed Original ResearchConceptsAdvanced breast cancerCardiac toxicityBreast cancerLiposomal doxorubicinTreatment cyclesCardiac safetyLeft ventricular ejection fraction reductionHER2/neu 2Median progression-free survivalVentricular ejection fraction reductionHER2-positive breast cancerClinical cardiac assessmentCumulative anthracycline dosesEjection fraction reductionNonpegylated Liposomal DoxorubicinGrade 3/4 neutropeniaObjective tumor responseHER2-positive patientsProgression-free survivalPhase I trialClinical cardiac toxicityAnthracycline dosesCytotoxic regimensFebrile neutropeniaTrastuzumab regimen
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply